First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $0 a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026.
- Net receivables increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Net Receivables vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 net receivables of $0 is the 8th highest of the 10 companies compared; the peer median is $583K.
- Net receivables amounts to 0.0% of total assets for TRAX, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.75M | +44.0% | +187.9% | 7.8% | |
| Mar 2026 | $5.76M | +92.9% | +182.0% | 1.4% | |
| Mar 2026 | $4.81M | +1825.6% | +125.7% | 2.4% | |
| Jun 2026 | $1.84M | — | -44.6% | 0.8% | |
| Mar 2026 | $583K | -23.4% | — | 0.4% | |
| Mar 2026 | $354K | -43.9% | +140.6% | 0.2% | |
| Sep 2026 | $138K | -93.0% | +64.6% | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | — | — | 0.0% | |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $583K | -23.4% | +133.1% | 0.4% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.